Scandion Oncology announce change to its Executive Management

Maj Hedtjärn has decided to resign from her position as Chief Operating Officer and Head of R&D Operations. She will leave Scandion Oncology no later than December 31, 2022.

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, announces that Maj Hedtjärn, Chief Operating Officer, Head of R&D Operations and member of Executive Management, has decided to resign from her position to pursue new opportunities outside Scandion.

Maj Hedtjärn will leave Scandion no later than December 31, 2022, allowing the company sufficient time to plan the optimal future setup for handling her tasks and responsibilities.

“While I of course respect Maj’s decision, I also regret it. Maj has been instrumental in the strengthening of Scandion during the past couple of years, including strong execution of our programs, de-risking of our lead asset SCO-101 and the build-up of our organization. Scandion is a much stronger company today than when Maj joined, and I thank her sincerely for her significant contributions and tireless efforts”, says Bo Rode Hansen, President & CEO of Scandion.

For further information please contact:

Mads Kronborg, Head of External Communication

Phone: +45 6051 4955


This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on August 30, 2022, at 08.55 CET.

Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.

Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). 

Västra Hamnen Corporate Finance is the Company’s certified advisor on Nasdaq First North Growth Market and can be reached at or +46 (0) 40 200 250.